Louis Garguilo

ARTICLES BY LOUIS

  • 9/7/2026

    "I should have known," writes Chief Editor Louis Garguilo, "It takes an accomplished biologist to most effectively describe the significance of artificial intelligence in our outsourcing industry, and put it to practical use." That professional is Damiano Dragone, Founder & Principal Advisor, Dragone Consulting, who built a career across pharmaceutical quality and data-driven quality environments within the biopharmaceutical industry, and was an early proponent of the promise of AI in quality, development and manufacturing, and the supply chain. 

  • 9/3/2026

    The FDA informed us again in April that the Bloomington, Indiana, facilities owned by Catalent until sold to Novo Nordisk in December 2024, have not solved quality issues. This adds to an FDA inspection/poor response and remediation history years long in the making. How is it we are witnessing this at a U.S. facility run by a name-brand CDMO and then Big Pharma? Catalent, for its part, wants to stop "inaccuracies in media coverage." Here's analysis from an experienced pharma professional and our own Chief Editor Louis Garguilo.

  • 8/31/2026

    Innovation requires new thinking and approaches. It also heightens the need for disciplined execution. With ATMP development – as well as with any program – starting out on a path lined with outsourcing principles may prove your greatest competitive advantage. A discussion from Chief Editor Louis Garguilo.

  • 8/24/2026

    The search for supply chain partners goes on. Intensely. But productively? Are we missing anything? We are about to learn the answer to that is yes.  Alan Davis, President & CEO, i5 Services says puzzling is how little these searches vary – and he's concerned that invariance has negative national supply-chain implications. He has a mission and a search platform to change that.

  • 8/17/2026

    Chief Editor Louis Garguilo superimposes two reports: one on a precise subject, cold chain monitoring; the second an analysis of the entire contract manufacturing market.  What brings the two together? "Growth, its various components, and interpretations." The cold chain monitoring report is prime example of the components of growth demonstrated in the overall biopharma outsourcing market report.

  • 8/14/2026

    A lower-court ruling does not make a victory. But it adds a little sanity to this melodrama. On August 7, a U.S. District Judge did something that has been surprisingly rare in the long-running WuXi AppTec/BIOSECURE Act saga: He looked at the U.S. government's case for labeling WuXi a “Chinese military company” and decided the government had not shown enough evidence. Analysis from Chief Editor Louis Garguilo.

  • 8/10/2026

    Tales of purpose-led careers that bring innovations to business leaders and opportunities to university students. They inspire us. Chief Editor Louis Garguilo documents two such professionals who have combined to help domestic manufacturing organizations locate each other and power their operations, and to get students involved in the industry.

  • 8/3/2026

    Asset development and outsourcing strategies can be intriguing, and full of global connections. Those attributes surface immediately in a conversation with Hyung Heon Kim, Chief Executive Officer and President, MetaVia, a Cambridge, Mass.-based biotech. The company reformed recently, but has roots back to 90 years of South Korean pharma history. Tracing the CDMO relationship MetaVia has is also part of the organization’s history. “Ours is a fun journey to tell,” says Kim. Fun, informative, and enlightening.

  • 7/27/2026

    CDMO mergers and acquisitions and the addition of services has been a dominating trend in outsourcing; comprehensive offerings and scale are proclaimed indispensable to customers. Sufficient time has now elapsed so we can evaluate this era of more and those claims.  Chief Editor Louis Garguilo looks into the evidence, and comes up with some interesting developments.

  • 7/23/2026

    We've acquired one of the industry's fastest-growing outsourcing conference franchises. We’re back in the live events business; that's great news. This new partnership also sets us to wondering: As an outsourcing industry, where in fact are we regarding in-person and virtual events? I asked my new colleagues, the co-founders of PharmaSource and CDMO Live conferences, Luke Bilton and Chris Kilbee.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.